Pangea Biomed
Pangea Biomed is an Israel-based precision oncology company whose ENLIGHT platform uses multi-omics and machine learning to predict patient cancer treatment response and rank therapeutic options. It sells ENLIGHT-NGS RNA-based drug matching tests and is launching ENLIGHT-DP for H&E slide-based predictions, serving hospitals, cancer centers, and biopharmaceutical partners.
- Company typePrivate
- Founded2018
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Pangea Biomed does
Pangea Biomed is an Israel-based precision oncology company founded in 2018 that develops the ENLIGHT proprietary tumor intelligence platform for predicting patient response to cancer therapies. Rather than relying on actionable genomic mutations alone, ENLIGHT infers "gene social networks" of functional genetic interactions from multi-omics data (expression, epigenetics, proteomics) and ranks dozens of treatment options per patient with an ENLIGHT Matching Score. The company commercializes this capability through two products: ENLIGHT-NGS, an RNA-based drug matching test run on standard FFPE pathology samples and commercially available in several countries; and ENLIGHT-DP, which applies the DeepPT deep learning framework to predict tumor mRNA expression directly from H&E-stained histopathology slides, slated for commercial availability in 2025. DeepPT, validated across 16 TCGA cohorts, enables treatment matching without requiring NGS sequencing, materially lowering access barriers.
The company monetizes through two channels: (i) per-test or commercial availability of ENLIGHT-NGS for oncologists ordering treatment matching, and (ii) platform licensing or collaboration agreements with biopharmaceutical companies for drug discovery, target identification, and clinical trial design, with a dedicated Chief, Pharma Alliances executive leading the effort. Pangea Biomed's customer base spans biopharma companies (primary segment), hospitals and cancer centers (primary), and academic research institutions (secondary), with named engagements including OHSU Knight Cancer Institute, Hadassah University Hospital, Sheba Medical Center, the LiquidBX Consortium, and the US National Cancer Institute. The company has raised $12M in total seed funding led by NFX, is actively participating in major oncology conferences (ASCO, AACR, BIO), and has been recognized on Fast Company's 2024 Next Big Things in Tech list.
Pangea Biomed firmographics
Firmographics- Name
- Pangea Biomed
- Legal name
- Pangea Biomed
- Website
- https://pangeabiomed.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pangea Biomed is an Israel-based precision oncology company whose ENLIGHT platform uses multi-omics and machine learning to predict patient cancer treatment response and rank therapeutic options. It sells ENLIGHT-NGS RNA-based drug matching tests and is launching ENLIGHT-DP for H&E slide-based predictions, serving hospitals, cancer centers, and biopharmaceutical partners.
- Ownership category
- akta.pro rank
Pangea Biomed industry classification
Industry- Product category
- Precision Oncology Software & Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Pangea Biomed is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Pangea Biomed business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- ENLIGHT-NGS Commercial Testing: RNA-based drug matching tests commercially available in several countries. Physicians order tests derived from FFPE pathology samples to receive actionable treatment recommendations with ENLIGHT Matching Scores.
- Platform Licensing to Pharma: Biotech/pharma companies and research groups use the ENLIGHT platform for drug development and treatment nomination, likely through licensing agreements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | ENLIGHT-NGS commercial testing available by physician order |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Pangea Biomed product offering
Product offeringCore offering
Pangea Biomed develops and sells the ENLIGHT proprietary tumor intelligence platform, which analyzes molecular context (expression, epigenetics, proteomics) and genetic interactions to predict cancer treatment response. The company delivers two commercial products: ENLIGHT-NGS, an RNA-based drug matching test from FFPE sequencing samples, and ENLIGHT-DP (powered by DeepPT), a treatment matching test derived directly from H&E histopathology slides without requiring NGS. Both products assign ENLIGHT Matching Scores to dozens of treatment options per patient.
Product overview
Pangea Biomed offers the ENLIGHT proprietary tumor intelligence platform for precision oncology, consisting of two main commercial products: ENLIGHT-NGS (RNA-based drug matching from FFPE sequencing samples) and ENLIGHT-DP (treatment matching directly from H&E histopathology slides). Both products are powered by the ENLIGHT platform which uses genetic interaction analysis and machine learning to screen and rank dozens of treatment options per patient, assigning ENLIGHT Matching Scores. The DeepPT deep learning component enables transcriptomics prediction from standard pathology slides, extending accessibility of precision oncology.
Differentiator
Problem solved
Functional benefit
Brands
- ENLIGHT: Proprietary tumor intelligence platform that enables deeper understanding of how tumors respond to therapy by examining molecular context including expression abnormalities, epigenetics, and proteomics.
- ENLIGHT-NGS
- ENLIGHT-DP
- DeepPT
Products and services
- ENLIGHT-NGS ENLIGHT-NGS is an RNA-based drug matching analysis test driven by deep transcriptomic analysis. Based on sequencing derived from standard FFPE (Formalin Fixed, Paraffin Embedded) pathology samples, it delivers an actionable report helping physicians make informed treatment decisions. It screens dozens of treatment options, assigns each an ENLIGHT Matching Score, and categorizes matches by level of evidence. Commercially available in several countries with expansion planned.
- ENLIGHT-DP ENLIGHT-DP is a treatment matching analysis solution that works directly from H&E slides using DeepPT, Pangea's digital pathology deep learning platform combined with ENLIGHT. It computes ENLIGHT Matching Scores for dozens of drugs from standard H&E-stained pathology slides without the need to wait for NGS results. Scheduled for commercial availability in 2025.
- ENLIGHT Platform (Tumor Intelligence Platform) The ENLIGHT platform is Pangea's proprietary tumor intelligence platform consisting of two engines: the Inference Engine, which processes multiple big-data repositories to infer Genetic Interactions and produce GI Maps, and the Predictive Engine, which combines GI Maps with drug, pathway, and patient-specific multi-omics data to derive personalized treatment response predictions. It is offered to biopharmaceutical and research partners for drug discovery, indication expansion, and clinical trial design.
Quantifiable outcome
- 80% predictive success rate across 35 published targeted and immunotherapy clinical trials from 10 different cancer types
- +4 more outcomes
Companies that use Pangea Biomed
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Pangea Biomed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Pangea Biomed partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- OHSU Knight Cancer InstitutecorePilot collaboration to improve cancer therapy precision using the ENLIGHT platform. Joint effort to validate and deploy AI-powered treatment matching at a major US cancer center.
- Dr. Kenneth AldapeminorDr. Kenneth Aldape from the US National Cancer Institute joined Pangea Biomed's Scientific Advisory Board, bringing expertise in molecular neuropathology and tumor diagnostics.
- LiquidBX ConsortiumminorPangea joined the second phase of the LiquidBX consortium to improve cancer detection and treatment response prediction, collaborating with multiple industry partners.
- Hadassah University Hospital and Ultima GenomicscoreStrategic collaboration with Sharett Institute of Oncology and Hadassah Cancer Research Institute along with Ultima Genomics for solid tumor cancer treatment research, combining ENLIGHT with Ultima's genomic sequencing capabilities.
- Sheba Medical CentercoreOngoing collaboration with Sheba Medical Center for clinical research, including studies on PARP inhibitor response in BRCA-associated pancreatic cancer and other precision oncology applications.
- Research Institutions (Partner Logos)minorPangea engages with some of the most advanced and innovative medical institutions and research labs. The company maintains multiple institutional partnerships for clinical validation and research collaboration.
Scale indicators3 records
Recent moves6 records
Expansion highlights7 records
Pangea Biomed competitors and assessment
Company assessmentDirect peers
- Personalis: Cancer genomics company with a tumor-only DNA + whole-transcriptome (RNA) assay and a pharma biomarker/biopharma CDx business. Highly comparable to Pangea on the RNA-based response prediction approach and biopharma customer segment.
- Tempus Labs: AI-driven precision medicine company offering multi-omics profiling (DNA/RNA) and treatment recommendation reports for oncologists. Closest direct competitor to ENLIGHT-NGS, with similar model of combining sequencing + ML for therapy matching, and a parallel pharma services business.
- Caris Life Sciences: Offers molecular profiling (DNA, RNA, protein) plus an AI platform (MI Profile, MI Cancer Seek) that pairs with treatment recommendations. Directly comparable in the molecular treatment-matching category with a substantial pharma ADX/biomarker business.
- Strata Oncology: Precision oncology platform delivering molecular profiling reports to oncologists and running a large prospective observational trial (Strata Sentinel). Comparable in the tumor profiling + treatment matching category with similar enterprise health-system GTM motion.
Emerging players
- PathAI: AI/digital pathology company applying deep learning to H&E slides, including a biomarker/companion diagnostics business. Closest analogue to Pangea's DeepPT (image-to-transcriptomics) approach and an obvious strategic or competitive counterparty in the H&E-based treatment matching space.
- Owkin: AI-for-drug-discovery and diagnostics company applying ML to multi-modal patient data for biomarker and target discovery, with a meaningful pharma services business. Comparable on the AI/ML + multi-omics + pharma customer model, though more drug-discovery-weighted.
- Predicine: Liquid biopsy + AI company offering genomics and transcriptomics-based tests for therapy selection and clinical trial biomarker work. Comparable technology stack and customer base but smaller and earlier-stage than Pangea's institutional peers.
Broad incumbents
- NeoGenomics: Established oncology-focused clinical lab services company with a growing proprietary profiling and pharma services business (e.g., RaDaR, NGS panels). Comparable in hospital/cancer-center oncology testing GTM, but much broader and more diversified.
- Guardant Health: Liquid biopsy leader with Guardant360 CDx and a growing multi-omics + therapy selection franchise. Comparable in oncology treatment selection, though dominated by liquid biopsy rather than tissue-based RNA; offers a useful scale and reimbursement benchmark.
- Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology treatment selection. Directly comparable as a molecular profiling + clinical reporting service for oncologists, but operates at vastly larger scale and as part of a global diagnostics platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pangea Biomed social profiles
Digital presencePangea Biomed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pangea Biomed leadership team
Management profileNumber of profiles
Profiles6 records
Pangea Biomed funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pangea Biomed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pangea Biomed
What does Pangea Biomed do?
Pangea Biomed develops and sells the ENLIGHT proprietary tumor intelligence platform, which analyzes molecular context (expression, epigenetics, proteomics) and genetic interactions to predict cancer treatment response. The company delivers two commercial products: ENLIGHT-NGS, an RNA-based drug matching test from FFPE sequencing samples, and ENLIGHT-DP (powered by DeepPT), a treatment matching test derived directly from H&E histopathology slides without requiring NGS. Both products assign ENLIGHT Matching Scores to dozens of treatment options per patient.
Is Pangea Biomed a public or private company?
Pangea Biomed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pangea Biomed founded?
Pangea Biomed was founded in 2018. It employs 11 to 50 people.
Where is Pangea Biomed based?
Pangea Biomed is headquartered in Tel Aviv, Israel, in the Middle East region.
How does Pangea Biomed make money?
Two revenue lines are on record. ENLIGHT-NGS Commercial Testing is the primary driver. The others are platform Licensing to Pharma.
Who are Pangea Biomed's main competitors?
Direct peers on record are Personalis, Tempus Labs, Caris Life Sciences and Strata Oncology. Emerging players are PathAI, Owkin and Predicine. Broad incumbents are NeoGenomics, Guardant Health and Foundation Medicine.
Does Pangea Biomed have an API?
No public API is recorded for Pangea Biomed.
What industry is Pangea Biomed in?
Pangea Biomed's product category is Precision Oncology Software & Diagnostics. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.